305 related articles for article (PubMed ID: 36803535)
1. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
Barlassina A; González-López TJ; Cooper N; Zaja F
Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
[TBL] [Abstract][Full Text] [Related]
2. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
Cooper N; Hill QA; Grainger J; Westwood JP; Bradbury C; Provan D; Thachil J; Ramscar N; Roy A
Acta Haematol; 2021; 144(4):418-426. PubMed ID: 33789275
[TBL] [Abstract][Full Text] [Related]
3. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
[TBL] [Abstract][Full Text] [Related]
4. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.
Carpenedo M; Baldacci E; Baratè C; Borchiellini A; Buccisano F; Calvaruso G; Chiurazzi F; Fattizzo B; Giuffrida G; Rossi E; Palandri F; Scalzulli PR; Siragusa SM; Vitucci A; Zaja F
Ther Adv Hematol; 2021; 12():20406207211048361. PubMed ID: 34646432
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
Cooper N; Scully M; Percy C; Nicolson PLR; Lowe G; Bagot CN; Thachil J; Grech H; Nokes T; Hill QA; Bradbury C; Talks K; Dutt T; Evans G; Pavord S; Wexler S; Charania A; Collington SJ; Ervin A; Ramscar N; Provan D
Br J Haematol; 2024 Jun; 204(6):2442-2452. PubMed ID: 38429869
[TBL] [Abstract][Full Text] [Related]
6. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
Iino M; Sakamoto Y; Sato T
Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
[TBL] [Abstract][Full Text] [Related]
7. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Zhang X; Chuai Y; Nie W; Wang A; Dai G
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J; Lo M; Bubalo J
Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
[TBL] [Abstract][Full Text] [Related]
10. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.
Zaja F; Carpenedo M; Baratè C; Borchiellini A; Chiurazzi F; Finazzi G; Lucchesi A; Palandri F; Ricco A; Santoro C; Scalzulli PR
Blood Rev; 2020 May; 41():100647. PubMed ID: 31818701
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.
Cuker A; Lal L; Roy A; Elliott C; Carlyle M; Martin C; Haenig J; Viana R
Ann Hematol; 2022 Sep; 101(9):1915-1924. PubMed ID: 35849155
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
14. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
Červinek L; Mayer J; Doubek M
Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
[TBL] [Abstract][Full Text] [Related]
15. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
[TBL] [Abstract][Full Text] [Related]
17. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany.
Meyer O; Richter H; Lebioda A; Schill M
Hematology; 2021 Dec; 26(1):697-708. PubMed ID: 34547980
[TBL] [Abstract][Full Text] [Related]
19. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.
Cuker A; Despotovic JM; Grace RF; Kruse C; Lambert MP; Liebman HA; Lyons RM; McCrae KR; Pullarkat V; Wasser JS; Beenhouwer D; Gibbs SN; Yermilov I; Broder MS
Res Pract Thromb Haemost; 2021 Jan; 5(1):69-80. PubMed ID: 33537531
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin receptor agonists: ten years later.
Ghanima W; Cooper N; Rodeghiero F; Godeau B; Bussel JB
Haematologica; 2019 Jun; 104(6):1112-1123. PubMed ID: 31073079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
